{"filing":{"accession_number":"0001437749-26-022398","cik":"0002030617","ticker":"PMI","company_name":"Picard Medical, Inc.","form":"8-K","filing_date":"2026-07-02","report_date":null,"primary_document":"pmi20251008_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2030617/000143774926022398/pmi20251008_8k.htm"},"events":[{"id":15693,"run_id":13992,"accession_number":"0001437749-26-022398","anchor_item_number":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"summary":"The filing discloses a pre-recorded presentation released in advance of the Company's 2026 Annual Meeting of Stockholders (July 17, 2026), highlighting business progress, product development milestones (including the Emperor platform development roadmap with FDA Breakthrough Device designation pursuit and planned 2028 IDE submission), and financial performance (85% YoY revenue increase, 28% gross margin). While the Item 8.01 disclosure is routine in form, the substantive content—particularly the detailed Emperor platform development timeline and manufacturing optimization initiatives—constitutes material operational and strategic business updates that would affect a reasonable investor's assessment of the company's progress and future prospects. The filing is checked as Rule 425 written communications, suggesting M\u0026A context, though no explicit M\u0026A activity is disclosed in the body.","company_name":"Picard Medical, Inc.","ticker":"PMI","filing_date":"2026-07-02","form":"8-K","submitted_at":null,"items":null}],"classifications":[{"id":13566,"accession_number":"0001437749-26-022398","item_number":null,"item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"The filing discloses a pre-recorded presentation released in advance of the Company's 2026 Annual Meeting of Stockholders (July 17, 2026), highlighting business progress, product development milestones (including the Emperor platform development roadmap with FDA Breakthrough Device designation pursuit and planned 2028 IDE submission), and financial performance (85% YoY revenue increase, 28% gross margin). While the Item 8.01 disclosure is routine in form, the substantive content—particularly the detailed Emperor platform development timeline and manufacturing optimization initiatives—constitutes material operational and strategic business updates that would affect a reasonable investor's assessment of the company's progress and future prospects. The filing is checked as Rule 425 written communications, suggesting M\u0026A context, though no explicit M\u0026A activity is disclosed in the body.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-02T12:16:39.704994+00:00","company_name":"Picard Medical, Inc.","ticker":"PMI","filing_date":"2026-07-02"}]}